Positive News SentimentPositive NewsNASDAQ:PRPH ProPhase Labs (PRPH) Stock Forecast, Price & News $8.08 -0.05 (-0.62%) (As of 06/9/2023 ET) Add Compare Share Share Today's Range$7.76▼$8.2550-Day Range$7.50▼$9.7852-Week Range$6.60▼$15.25Volume105,295 shsAverage Volume84,883 shsMarket Capitalization$138.81 millionP/E Ratio19.71Dividend YieldN/APrice Target$14.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media ProPhase Labs MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside73.3% Upside$14.00 Price TargetShort InterestHealthy2.55% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.54Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.34) to $0.11 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.34 out of 5 starsMedical Sector357th out of 988 stocksPharmaceutical Preparations Industry164th out of 482 stocks 3.0 Analyst's Opinion Consensus RatingProPhase Labs has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $14.00, ProPhase Labs has a forecasted upside of 73.3% from its current price of $8.08.Amount of Analyst CoverageProPhase Labs has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.55% of the float of ProPhase Labs has been sold short.Short Interest Ratio / Days to CoverProPhase Labs has a short interest ratio ("days to cover") of 5.6.Change versus previous monthShort interest in ProPhase Labs has recently decreased by 4.05%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldProPhase Labs does not currently pay a dividend.Dividend GrowthProPhase Labs does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PRPH. Previous Next 3.6 News and Social Media Coverage News SentimentProPhase Labs has a news sentiment score of 1.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.82 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for ProPhase Labs this week, compared to 2 articles on an average week.Search Interest16 people have searched for PRPH on MarketBeat in the last 30 days. This is an increase of 78% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added ProPhase Labs to their MarketBeat watchlist in the last 30 days. This is a decrease of -44% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ProPhase Labs insiders have not sold or bought any company stock.Percentage Held by Insiders32.50% of the stock of ProPhase Labs is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.75% of the stock of ProPhase Labs is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ProPhase Labs are expected to grow in the coming year, from ($0.34) to $0.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ProPhase Labs is 19.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 130.08.Price to Earnings Ratio vs. SectorThe P/E ratio of ProPhase Labs is 19.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.68.Price to Book Value per Share RatioProPhase Labs has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ProPhase Labs (NASDAQ:PRPH) StockProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Garden City, NY.Read More Receive PRPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ProPhase Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address PRPH Stock News HeadlinesJune 7, 2023 | finance.yahoo.comProPhase Labs to Present at the Diamond Equity Research Emerging Growth Invitational on Tuesday, June 13, 2023June 2, 2023 | msn.comHC Wainwright & Co. Reiterates ProPhase Labs (PRPH) Buy RecommendationJune 10, 2023 | Behind the Markets (Ad)[BREAKING] Small Firm Develops World's First Anti-Aircraft LaserSmall cap wins $1.65 billion contract to make them. GlobeNewswire says this is a $51.1 Billion market by 2026. See why this stock could soar 2,476% >>>June 2, 2023 | markets.businessinsider.comH.C. Wainwright Remains a Buy on Prophase Labs (PRPH)June 1, 2023 | finance.yahoo.comProPhase Labs’ Cancer Therapeutic, Linebacker-1, pre-clinical studies with Dana Farber/Harvard Cancer Institute demonstrate impressive utility and move into next phase of testingMay 20, 2023 | americanbankingnews.comFY2023 EPS Estimates for ProPhase Labs, Inc. Raised by Diamond Equity (NASDAQ:PRPH)May 15, 2023 | americanbankingnews.comHC Wainwright Trims ProPhase Labs (NASDAQ:PRPH) Target Price to $14.00May 13, 2023 | markets.businessinsider.comHere's what Wall Street expects from ProPhase Labs's earnings reportJune 10, 2023 | Vantage Point (Ad)Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market. May 12, 2023 | msn.comHC Wainwright & Co. Maintains ProPhase Labs (PRPH) Buy RecommendationMay 12, 2023 | markets.businessinsider.comAnalyst Expectations for ProPhase Labs's FutureMay 11, 2023 | msn.comRecap: ProPhase Labs Q1 EarningsMay 11, 2023 | finance.yahoo.comProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2023May 11, 2023 | finance.yahoo.comProPhase Labs, Inc. (PRPH) Beats Q1 Earnings and Revenue EstimatesMay 10, 2023 | msn.comProPhase Labs Q1 2023 Earnings PreviewMay 8, 2023 | marketwatch.comProPhase Labs hires Dr. Matthew Halpert to Drive Company's Key Therapeutic and Diagnostic Oncology ProgramsMay 8, 2023 | finance.yahoo.comProPhase Labs hires Dr. Matthew Halpert to Drive Company’s Key Therapeutic and Diagnostic Oncology ProgramsMay 6, 2023 | americanbankingnews.comResearch Analysts Offer Predictions for ProPhase Labs, Inc.'s Q1 2023 Earnings (NASDAQ:PRPH)May 4, 2023 | finance.yahoo.comProPhase Labs to Host First Quarter 2023 Financial Results Conference Call on Thursday, May 11, 2023 at 11:00 a.m. Eastern TimeMay 3, 2023 | finance.yahoo.comProPhase Labs, Inc. (PRPH) Surges 8.5%: Is This an Indication of Further Gains?May 3, 2023 | finance.yahoo.comProPhase Labs’ Linebacker-1 Cancer Therapeutic shows promising mechanisms of action as both a mono-therapy and co-therapy in preclinical studies attacking a range of hard-to-treat cancers, including lung and gastric cancersMay 1, 2023 | finance.yahoo.comDiamond Equity Research Initiates Coverage on ProPhase Labs Inc. (NASDAQ: PRPH)April 29, 2023 | marketwatch.comProPhase Labs CEO Ted Karkus Named One of Inc Magazine's 10 Most Innovative Healthcare Leaders to Watch in 2023April 28, 2023 | finance.yahoo.comProPhase Labs CEO Ted Karkus Named One of Inc Magazine’s 10 Most Innovative Healthcare Leaders to Watch in 2023April 27, 2023 | markets.businessinsider.com7 Small-Cap Biotech Stocks with Massive PotentialApril 27, 2023 | finance.yahoo.comCOMSovereign Names Bill White, CFE as New Independent Director and Chair of Audit CommitteeApril 27, 2023 | finance.yahoo.comCould The Market Be Wrong About ProPhase Labs, Inc. (NASDAQ:PRPH) Given Its Attractive Financial Prospects?See More Headlines PRPH Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PRPH Company Calendar Last Earnings3/28/2023Today6/10/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PRPH CUSIPN/A CIK868278 Webwww.prophaselabs.com Phone(215) 345-0919Fax215-345-5920Employees95Year FoundedN/APrice Target and Rating Average Stock Price Forecast$14.00 High Stock Price Forecast$14.00 Low Stock Price Forecast$14.00 Forecasted Upside/Downside+73.3%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)$0.41 Trailing P/E Ratio19.71 Forward P/E RatioN/A P/E GrowthN/ANet Income$18.46 million Net Margins6.91% Pretax Margin8.01% Return on Equity10.05% Return on Assets6.89% Debt Debt-to-Equity Ratio0.16 Current Ratio3.32 Quick Ratio3.08 Sales & Book Value Annual Sales$122.65 million Price / Sales1.13 Cash Flow$1.44 per share Price / Cash Flow5.62 Book Value$3.91 per share Price / Book2.07Miscellaneous Outstanding Shares17,180,000Free Float11,599,000Market Cap$138.81 million OptionableNot Optionable Beta-0.33 Key ExecutivesTed William KarkusChairman & Chief Executive OfficerRobert A. MorseChief Financial & Accounting OfficerKey CompetitorsEvofem BiosciencesNASDAQ:EVFMReviva PharmaceuticalsNASDAQ:RVPHChimerixNASDAQ:CMRXDURECTNASDAQ:DRRXOrganigramNASDAQ:OGIView All CompetitorsInstitutional OwnershipState Street CorpBought 3,000 shares on 5/16/2023Ownership: 0.240%First Trust Advisors LPBought 2,678 shares on 5/16/2023Ownership: 0.210%Susquehanna International Group LLPBought 1,100 shares on 5/16/2023Ownership: 0.000%Bank of America Corp DEBought 7,920 shares on 5/12/2023Ownership: 0.222%Group One Trading L.P.Bought 1,000 shares on 5/12/2023Ownership: 0.000%View All Institutional Transactions PRPH Stock - Frequently Asked Questions Should I buy or sell ProPhase Labs stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ProPhase Labs in the last twelve months. There are currently 1 sell rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" PRPH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRPH, but not buy additional shares or sell existing shares. View PRPH analyst ratings or view top-rated stocks. What is ProPhase Labs' stock price forecast for 2023? 2 Wall Street analysts have issued 1-year target prices for ProPhase Labs' shares. Their PRPH share price forecasts range from $14.00 to $14.00. On average, they anticipate the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 73.3% from the stock's current price. View analysts price targets for PRPH or view top-rated stocks among Wall Street analysts. How have PRPH shares performed in 2023? ProPhase Labs' stock was trading at $9.63 at the beginning of the year. Since then, PRPH stock has decreased by 16.1% and is now trading at $8.08. View the best growth stocks for 2023 here. When is ProPhase Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our PRPH earnings forecast. How were ProPhase Labs' earnings last quarter? ProPhase Labs, Inc. (NASDAQ:PRPH) posted its earnings results on Tuesday, March, 28th. The company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of $0.02 by $0.10. The firm earned $21.82 million during the quarter, compared to the consensus estimate of $20.53 million. ProPhase Labs had a net margin of 6.91% and a trailing twelve-month return on equity of 10.05%. What ETF holds ProPhase Labs' stock ? First Trust Dow Jones Select Microcap Index Fund holds 35,105 shares of PRPH stock, representing 0.18% of its portfolio. What is Ted Karkus' approval rating as ProPhase Labs' CEO? 2 employees have rated ProPhase Labs Chief Executive Officer Ted Karkus on Glassdoor.com. Ted Karkus has an approval rating of 100% among the company's employees. This puts Ted Karkus in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of ProPhase Labs own? Based on aggregate information from My MarketBeat watchlists, some companies that other ProPhase Labs investors own include VIVUS (VVUS), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Fulcrum Therapeutics (FULC), Novus Therapeutics (NVUS), Onconova Therapeutics (ONTX) and Recro Pharma (REPH). What is ProPhase Labs' stock symbol? ProPhase Labs trades on the NASDAQ under the ticker symbol "PRPH." Who are ProPhase Labs' major shareholders? ProPhase Labs' stock is owned by many different institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (2.12%), BlackRock Inc. (0.64%), Acadian Asset Management LLC (0.58%), American Century Companies Inc. (0.48%), Bank of New York Mellon Corp (0.38%) and State Street Corp (0.24%). Insiders that own company stock include Jason Michael Barr and Ted William Karkus. View institutional ownership trends. How do I buy shares of ProPhase Labs? Shares of PRPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ProPhase Labs' stock price today? One share of PRPH stock can currently be purchased for approximately $8.08. How much money does ProPhase Labs make? ProPhase Labs (NASDAQ:PRPH) has a market capitalization of $138.81 million and generates $122.65 million in revenue each year. The company earns $18.46 million in net income (profit) each year or $0.41 on an earnings per share basis. How can I contact ProPhase Labs? ProPhase Labs' mailing address is 621 NORTH SHADY RETREAT ROAD, DOYLESTOWN PA, 18901. The official website for the company is www.prophaselabs.com. The company can be reached via phone at (215) 345-0919, via email at ir@prophaselabs.com, or via fax at 215-345-5920. This page (NASDAQ:PRPH) was last updated on 6/10/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.